Back to results
US 2022/0177586 A1Published application
Cd8 binding agents
AssigneesOrionis Biosciences BV, Vib Vzw, Universiteit Gent
InventorsNikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Sarah GERLO
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
Claims20
-28. (canceled)
A chimeric protein comprising:
- (a) a targeting moiety directed against CD8, the targeting moiety comprising three complementarity determining regions (CDR1, CDR2, and CDR3), wherein:
- (i) CDR1 comprises an amino acid sequence selected from GFTFDDYAMS (SEQ ID NO:12) and GFTFDDYAIG (SEQ ID NO:13);
- (ii) CDR2 comprises an amino acid sequence selected from TINWNGGSAEYAEPVKG (SEQ ID NO:14) and CIRVSDGSTYYADPVKG (SEQ ID NO:15);
- and
- (iii) CDR3 comprises an amino acid sequence selected from KDADLVWYNLS (SEQ ID NO:16), KDADLVWYNLR (SEQ ID NO:17), and AGSLYTCVQSIVVVPARPYYDMDY (SEQ ID NO:18), and
- (b) a signaling agent selected from one or more of an interferon, an interleukin, and a tumor necrosis factor.
3 more elements
Dependencies are inferred from the claim text.